Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $56.5 million versus the consensus estimate of $52 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.